Literature DB >> 16288376

Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.

Nigel Bourne1, Gregg N Milligan, Lawrence R Stanberry, Rachael Stegall, Richard B Pyles.   

Abstract

In recent clinical trials, a vaccine that contained herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) and the adjuvant AS04 afforded HSV-seronegative women significant protection against HSV-2 genital disease and limited protection against infection. Similarly, in guinea pigs, immunization with the vaccine provided significant protection against genital HSV-2 disease but did not prevent mucosal infection. We explored the impact of immunization on the magnitude of latent virus infection and on the frequency and magnitude of virus reactivation as measured by both recurrent disease and viral shedding into the genital tract. Guinea pigs immunized with gD2/AS04 were shown by quantitative polymerase chain reaction (qPCR) analysis to have significantly less latent viral DNA in the ganglia than did naive control guinea pigs and to have a reduced incidence and frequency of recurrent disease. By contrast, all immunized guinea pigs shed virus into the genital tract with a frequency comparable to that seen in control guinea pigs. However, the amount of virus shed was significantly reduced, as measured by qPCR. These data suggest that immunization could affect transmission by altering viral shedding patterns.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288376     DOI: 10.1086/498247

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

Authors:  Barbara C Baudner; Vanessa Ronconi; Daniele Casini; Marco Tortoli; Jina Kazzaz; Manmohan Singh; Lynn D Hawkins; Andreas Wack; Derek T O'Hagan
Journal:  Pharm Res       Date:  2009-03-03       Impact factor: 4.200

2.  Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.

Authors:  Marina Boukhvalova; Jamall McKay; Aissatou Mbaye; Hannah Sanford-Crane; Jorge C G Blanco; Ashley Huber; Betsy C Herold
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

Review 3.  Vaccines to prevent genital herpes.

Authors:  Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

4.  Development of disease and immunity at the genital epithelium following intrarectal inoculation of male guinea pigs with herpes simplex virus type 2.

Authors:  Nigel Bourne; Brianne N Banasik; Clarice L Perry; Aaron L Miller; Mellodee White; Richard B Pyles; Gregg N Milligan
Journal:  Virology       Date:  2018-11-06       Impact factor: 3.616

5.  Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

Authors:  Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Sci Immunol       Date:  2019-09-20

6.  Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.

Authors:  Richard Brans; Feng Yao
Journal:  BMC Microbiol       Date:  2010-06-03       Impact factor: 3.605

7.  Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine.

Authors:  William P Halford; Ringo Püschel; Brandon Rakowski
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

8.  Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1.

Authors:  Richard Brans; Natali V Akhrameyeva; Feng Yao
Journal:  J Invest Dermatol       Date:  2009-04-09       Impact factor: 8.551

9.  A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Authors:  Ronald L Veselenak; Mark Shlapobersky; Richard B Pyles; Qun Wei; Sean M Sullivan; Nigel Bourne
Journal:  Vaccine       Date:  2012-10-04       Impact factor: 3.641

10.  Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection.

Authors:  Clarice L Perry; Brianne N Banasik; Summer R Gorder; Jingya Xia; Sarah Auclair; Nigel Bourne; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2016-09-19       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.